Alemtuzumab is a humanized IgG1 kappa antibody directed against CD52, a glycosyl-phosphatidylinositol linked cellmembrane protein of unknown function. Herein, we demonstrate that alemtuzumab promotes rapid death of chronic lymphocytic leukemia (CLL) cells in vitro, in a complement and accessory cell free system. Using minimal detergent solubilization of CLL membranes, we found that CD52 colocalizes with ganglioside GM-1, a marker of membrane rafts. Fluorescence microscopy revealed that upon crosslinking CD52 with alemtuzumab þ anti-Fc IgG, large patches, and in many cases caps, enriched in CD52 and GM-1 formed upon the CLL cell plasma membrane. Depletion of membrane cholesterol or inhibition of actin polymerization significantly diminished the formation of alemtuzumab-induced caps and reduced alemtuzumab-mediated CLL cell death. We compared alemtuzumab-induced direct cytotoxicity, effector cell-mediated toxicity and complement-mediated cytotoxicity of CLL cells to normal T cells. The direct cytotoxicity and observed capping was significantly greater for CLL cells as compared to normal T cells. Cell-mediated and complement-mediated cytotoxicity did not significantly differ between the two cell types. In summary, our data support the hypothesis that alemtuzumab can initiate CLL cell death by crosslinking CD52-enriched lipid rafts. Furthermore, the differential direct cytotoxic effect suggests that CD52 directed antibodies could possibly be engineered to more specifically target CLL cells.
Introduction
Alemtuzumab is a humanized IgG1 kappa antibody directed against the cell surface antigen CD52, a 12 amino acid, glycosyl-phosphatidylinositol (GPI) linked protein. 1, 2 While the function of CD52 is unknown, it is abundantly expressed on normal B and T lymphocytes, monocytes, macrophages, natural killer cells and dendritic cells, [3] [4] [5] as well as epididymal tissues. 6 Corresponding to normal hematopoetic expression, the CD52 antigen is expressed on varying subsets of tumor cells derived from patients with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia, multiple myeloma, Non-Hodgkin's lymphoma, T-cell lymphoproliferative disorders and acute lymphoid leukemia. For CLL, expression of the CD52 antigen is virtually uniform on all tumor cells. 7 The development of alemtuzumab in clinical practice was initially focused upon autoimmune diseases but was subsequently found to be effective in treating lymphoproliferative disorders such as CLL. [8] [9] [10] [11] These studies in CLL and other diseases have substantiated the clinical role for alemtuzumab, and provide further justification for elucidating the mechanisms of alemtuzumab's biologic effect.
To date, little is known about how alemtuzumab mediates its biologic effect in vivo. Preclinical studies have demonstrated that alemtuzumab and other rat IgG and IgM anti-CD52 directed antibodies mediate CDC and ADCC in vitro. [12] [13] [14] [15] Two additional studies have demonstrated varied biologic effects of CD52 ligation with respect to cytotoxicity in normal T cells and isolated transformed B cells in vitro. In normal T cells, ligation of CD52 with alemtuzumab and a secondary crosslinking antibody in the presences of phorbol myristate acetate leads to activation and proliferation. 16 Contrasting with this, when a transformed B cell line that expresses CD52 is treated with alemtuzumab and a secondary IgG crosslinking antibody, cell death and growth arrest is noted. 17 Two recent studies have examined the effect of alemtuzumab on CLL cells in the absence of ADCC or CDC; however, with regards to direct alemtuzumab-meditated killing, the results of these two studies are conflicting. 18, 19 We and others have demonstrated that monoclonal antibodies targeting the CD20, [20] [21] [22] [23] CD47 24 or HLA-DR 25, 26 antigens on CLL cells directly initiate cell death. Given the effectiveness of alemtuzumab in killing CLL cells in vivo, we considered that this agent might also have a similar direct cytotoxic effect. In a B-cell line, it has been shown that crosslinking of the GPI-linked membrane protein CD24, as well as other GPI-linked proteins, leads to cell death. 27 Thus, we hypothesized that crosslinking of CD52, by virtue of its GPI linkage, could directly kill CLL cells through a lipid raft-dependent mechanism. Herein, we examine the ability of alemtuzumab to induce cell death directly in primary CLL cells in vitro and we interrogate the mechanism by which this occurs.
Materials and methods
CLL, T cell and PBMC sample processing: blood was obtained from patients with CLL as defined by NCI96 criteria 28 following receipt of written informed consent under a IRB approved protocol at The Ohio State University. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood immediately following donation using ficoll density gradient centrifugation (Ficoll-Paque Plus, Amersham Biosciences, Piscataway, NJ, USA) and depleted of non-B cells using the Miltenyi Biotec (Auburn, CA, USA) B-Cell Isolation Kit. T cells were obtained from random blood donors using a technique to isolate mononuclear cells from leukocyte reduction filters 29 with subsequent negative selection of T cells using a pan T-cell isolation kit (Miltenyi Biotec, Auburn, CA, USA). The lymphocytic concentrate was greater than 90% CD3 positive cells as determined by FACS analysis. Isolated cells were incubated 371C and 5% CO 2 in RPMI 1640 media (Invitrogen Corp, Carlsbad, CA, USA) supplemented with 10% heat-inactivated FBS (Invitrogen Corp), 2 mM L-glutamine (Invitrogen Corp) and penicillin/streptomycin (Sigma-Aldrich Chemical Co, St Louis, MO, USA).
The anti-CD52 antibody alemtuzumab (Ilex Pharmaceuticals, San Antonio, TX, USA), anti-HER2-receptor trastuzumab, isotype IgG 1 kappa, (Genentech Inc., San Francisco, CA, USA), crossgoat anti-human IgG Fc gamma fragment specific (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA), Z-VAD-fmk, ALLN, Calpain inhibitor III and PD150606 (EMD Biosciences Inc., San Diego, CA, USA), cytochalasin D cycloheximide and actinomycin D and methyl-b-cyclodextrin (MbCD) (Sigma-Aldrich Chemical Co) were obtained commercially.
Assessment of antibody-treated CLL cells by flow cytometry
Dead cells were quantified using single agent propidium iodide (PI) staining or dual annexin V-fluorescein isothiocyantate (FITC)/PI (BD Pharmingen, San Diego, CA, USA) staining with FACS analysis with a Beckman-Coulter EPICS XL cytometer (Beckman-Coulter, Miami, FL, USA). 30 Assessment of mitochondrial integrity was determined using rhodamine-123 staining with FACS analysis as previously described. 26 Chromium-51 release assay for ADCC ADCC was measured using the chromium-51 release assay as described 15 with minor modifications. In all the ADCC experiments alemtuzumab was used at 10 mg/ml in supplemented RPMI media. Released chromium-51 was separated from intact cells using a filter device. Effector cells were random donor PBMC.
MTT assay
Following incubation with antibodies, the MTT assay was performed upon cells as previously described with minor alterations. 31 Cells were incubated for 6 h after the addition of the MTT reagent.
Western blot
Whole cellular lysates were prepared and immunobloting performed as previously described. 32 Antibodies included Caspase-3 (mAb AR-14, gift of John Reed, Burnham Institute, La Jolla, CA, USA), caspase-8 (mAb 3-1-9, BD Pharmingen), caspase-9 (mAb Ab-1, Oncogene Research, San Diego, CA, USA), PARP (mAb Ab-2, Oncogene Research), CD52 (campath-1G, Serotec Inc., Raleigh, NC, USA), CD45 (mAb 5-Z6, Santa Cruz Biotechnology, Santa Cruz, CA, USA), Lyn (pAb sc-15, Santa Cruz Biotechnology) and GAPDH (Chemicon International Inc., Temecula, CA, USA).
Isolation of detergent-insoluble glycolipid-enriched domains from CLL cells
Detergent-insoluble glycolipid-enriched domains (DIGs) were isolated essentially as described by Goebel et al. 33 The gradients were fractionated into 1 ml aliquots. To determine location of the DIGs within the gradient, 1 ml of each fraction was dotted onto a nitrocellulose membrane, probed with cholera toxin subunit Bhorseradish peroxidase (HRP) (Sigma-Aldrich Chemical Co).
Fluorescence microscopy evaluation of patching and capping on primary CLL cells CLL cells were incubated at 41C for 15 min with alemtuzumab (10 mg/ml) in RPMI 1640 media without FBS. Crosslinking antibody, TRITC labeled goat anti-human IgG Fc fragment specific (10 mg/ml) (Jackson ImmunoResearch Laboratories), was then added and the cells were incubated for another 15 min at 41C. Samples were then warmed to 371C and allowed to incubate for the desired times. For the CD52/GM1 colabeling experiments, the CD52 stained samples were incubated for an additional 5 min with 1 mg/ml cholera toxin subunit B-Alexa Fluor 488 (Molecular Probes Inc., Eugene, OR, USA). Samples were fixed (2% paraformaldehyde) and washed twice in PBS. Wet-mount slides were prepared and viewed with a Zeiss Axioskop 2 plus fluorescence microscope using the Zeiss AxioVision 4 imaging software (Carl Zeiss Microscopy, Gottingen, Germany). For each sample, at each condition, at least 200 cells were scored for capping. Lack of binding of the isotype control and TRITC labeled goat anti-human IgG Fc, as compared to alemtuzumab and the TRITC labeled goat anti-human IgG Fc, was confirmed by FACS analysis. Cells were treated with trastuzumab (10 mg/ml) or alemtuzumab (10 mg/ml), and then with the TRITC labeled secondary antibody (10 mg/ml). Cells were washed and analyzed in a blinded fashion.
Data analysis
A faculty statistician analyzed the data. P-values were calculated using the Mann-Whitney test for comparison of independent data sets. Data weres considered statistically significant if the P-value was less than 0.05.
Results

Alemtuzumab induces cell death in primary CLL cells
The direct cytotoxic effect of alemtuzumab upon CLL cells is significant (P-values o0.001) when compared to untreated control values ( Figure 1a ). alemtuzumab treatment resulted in an 11% cell death after a 4-h treatment that increased to 26% (s.d. 11) with a secondary crosslinking antibody. The MTT assay was used to confirm the finding of alemtuzumab-induced CLL cell death where similar results were observed.
The magnitude of the direct cytotoxic effect of alemtuzumab upon CLL cells is compared to values obtained for alemtuzumab directed ADCC and CDC in Figure 1b . To allow a more direct comparison among the different in vitro assays methods, cell death was defined by positive PI staining for direct cytotoxicity and CDC, and chromium-51 release for ADCC. For each of these assays CLL samples were treated for 4 h. The reported cytotoxicity is the percentage of dead cells above the respective untreated control sample. The direct cytotoxity of crosslinked alemtuzumab was 16% (s.d. 
Alemtuzumab-induced cell death is caspaseindependent
Apoptosis of CLL cells can occur through both caspasedependent pathways, involving activation of caspase 8 or caspase 9, or through caspase-independent pathways. Incubation of CLL cells with the pan-caspase inhibitor Z-VAD-fmk (150 mM) did not reduce alemtuzumab-induced killing ( Figure 2a) . Additionally, as shown in Figure 2b , immunoblot analysis shows no increase in caspase 3, 8, 9 or PARP processing above the control values. Figure 2c shows that little if any, small fragment DNA laddering occurs following alemtuzumab treatment of CLL cells for 12 h despite loss of mitochondrial membrane potential as shown in Figure 2d . This is further evidence that the alemtuzumab-initiated death we observed in vitro occurs through a unique mechanism as compared to the caspase-dependent pathways initiated by more standard CLL therapeutic agents. The mechanisms by which caspase-independent apoptosis occurred subsequently were shown to be independent of calpains, protein synthesis and RNA synthesis as suggested by specific calpain, protein synthesis, and RNA synthesis inhibitors to reduce alemtuzumab-induced cell death (data not shown).
CD52 is concentrated in detergent-insoluble, glycosphingolipid-enriched domains
Studies have demonstrated that many GPI-linked membrane proteins are concentrated within detergent-insoluble glycosphingolipid-enriched domains (DIGs) across the plasma membrane. [34] [35] [36] Given the minimal protein composition of CD52, the interaction of CD52 with the plasma membrane is likely dominated by the GPI moiety, thus we hypothesized that CD52 would be concentrated within DIG isolates of CLL cells. DIGs were isolated from CLL cells. 33 Aliquots from separate fractions were blotted onto a nitrocellulose membrane, and the membrane was probed for ganglioside GM-1, a marker of DIGs, 36, 37 using the cholera toxin subunit B-HRP. 38 Figure 3a shows that the cholera toxin subunit B derivative bound to isolates from fractions 6 and 7. These are the lower density fractions, between the 5 and 35% sucrose, and they are expected to be enriched with DIGs. 33 To determine the location of CD52 among the gradient fractions, an immunoprecipitation was performed upon equal volumes of each fraction, followed by SDS-PAGE and immunoblotting. Figure 3b shows that CD52 is concentrated among fractions 6 and 7 indicating that CD52 is preferentially located within DIGs. To determine the location of non-DIG membrane isolates, gradient fractions were immunoprecipitated with anti-CD45 with subsequent immunoblotting. Prior works have shown that most CD45 is not associated with DIGs in unstimulated cells. 27, [39] [40] [41] CD45 is concentrated within fractions 16-17; fractions 6 and 7 did not contain detectable CD45 indicating the effective separation of DIGs from the other membrane fractions (Figure 3b ). Lyn, a protein known to associate with DIGs was relatively concentrated in fractions 5-7 as expected. 42 These data provide evidence that CD52 is preferentially located in DIGs within CLL cell membranes.
Treatment of CLL cells with crosslinked alemtuzumab leads to the formation of large CD52 and ganglioside GM-1-enriched domains within the plasma membrane
The nature of DIGs, with respect to size, stability and composition, within plasma membranes under physiologic conditions is not entirely clear. 43, 44 However, considerable evidence suggests that aggregation within the plasma membrane of entities that can be the operationally defined as DIGs can initiate intracellular signaling. 45, 46 Indeed, crosslinking of glycosphingolipids, under physiologic conditions, using cholera toxin subunit B and anticholera toxin antibodies leads to patching and capping in lymphocytes and in some systems, cell death. 27, 47, 48 Having shown that DIG isolates from primary CLL cells are enriched with CD52, we sought to determine if crosslinking of CD52 with alemtuzumab formed aggregates of glycolipid-enriched domains within the CLL cell plasma membrane. As shown in Figure 4 Using alemtuzumab þ anti-Fc IgG-TRITC to label crosslinked CD52 and cholera toxin subunit B-Alexa Fluor to label glycolipid-enriched membrane domains, we found congruent staining patterns under fluorescence microscopy ( Figure 4c ). This is evidence that crosslinked alemtuzumab-induced patches and caps on CLL cells contain both CD52 and ganglioside GM-1. This data suggests that crosslinking of CD52 leads to formation of large DIG aggregates and caps in CLL cells.
IB -CD45
IB -CD5 CLL #1 CLL #2 Figure 3 CD52 co-localizes with ganglioside GM-1 and protein Lyn, markers of membrane lipid raft fractions. (a) Following solubilization, CLL lysate was centrifuged on a discontinuous sucrose gradient and then divided into 1 ml fractions, aliquoted onto nitrocellulose, and then developed using cholera toxin B subunit-HRP that binds to GM-1. (b) The indicated fractions from a) were immunoprecipitated using anti-CD45, anti-Lyn, or anti-CD52 (campath-1G) and the resulting product was analyzed by immunoblotting as shown. CD45, which minimally localizes to lipid rafts in untreated cells, serves as a negative control for the isolation of detergent insoluble membranes, whereas Lyn serves as a positive control.
Alemtuzumab-induced aggregation and capping of CD52 and ganglioside GM-1 is inhibited by depletion of membrane cholesterol and requires F-actin cytoskeletal rearrangement
Having shown that crosslinking of CD52 leads to the formation of large ganglioside GM-1 containing aggregates and caps in primary CLL cells, we sought further evidence that the link between CD52 and the microscopically observed membrane processes was the glycolipid-enriched domain. Glycolipidenriched domains can be disrupted by cholesterol depletion of the plasma membranes. 50, 51 Thus, we examined alemtuzumabinduced patching and capping in CLL lymphocytes depleted of membrane cholesterol with a MbCD solution. After treating CLL cells with MbCD, the formation of alemtuzumab þ anti-Fc IgG-TRITC CD52-enriched membrane caps is reduced to 8.2% (s.d. 6.7) ( Figure 5) . The difference in capping between samples treated with and without MbCD is significant with a P-value of 0.017. Analysis of the cholesterol depleted CLL cells with the MTT assay (data not shown) confirmed that MbCD treatment alone had only a small cytotoxic effect upon the cells over the time course of the experiments.
A previous study showed that patches of a-actinin, an F-actin binding protein, form under cholera toxin-induced membrane patches, and that capping of cholera toxin-ganglioside GM-1 complexes is accompanied by capping of a-actinin in lymphocytes. 48 Moreover, actin filaments accumulate under antibodyinduced patches of GPI-linked membrane proteins. 35 Thus, outer-leaflet components of glycolipid-enriched membrane domains are linked to the underlying F-actin cytoskeleton. Intriguingly, the cytochalasins, which are inhibitors of F-actin polymerization, have been shown to inhibit anti-HLA-DR and anti-CD47 antibody-induced lymphocyte cell death. 26, 52, 53 To begin to examine the link between glycolipid-enriched membrane domain aggregation, alteration of CLL cell cytoskeletal elements and the initiation of death signaling pathways, we examined the effect of cytochalasin D upon alemtuzumabinduced membrane capping. As illustrated in Figure 5 , cytochalasin D substantially reduced alemtuzumab-induced capping. Cytochalasin D pretreatment reduced alemtuzumab þ anti-Fc IgG-induced capping from 19 to 4.6% (s.d. 6.2), which is significant with a P-value of less than 0.001.
Disruption of lipid rafts with methyl-b-cyclodextrin or inhibition of actin cytoskeletal rearrangement inhibits alemtuzumab-induced CLL cell killing
Our data indicates that CD52 is concentrated in DIGs and that crosslinking of CD52 leads to coalescence of glycolipid-enriched membrane domains, thus we hypothesized that it is the coalescence of glycolipid-enriched domains by alemtuzumab that initiates events leading to CLL cell death. in parallel upon the isolated T cells using the same experimental conditions as those used in the ADCC and CDC assays upon the CLL cells. As illustrated by Figure 7a , there was no significant difference between CLL cells and T cells for either ADCC or CDC.
Discussion
We have shown that treatment of primary CLL cells with alemtuzumab in the absence of complement or immune effector cells, leads to rapid cell death in vitro through a death pathway that is caspase-independent. Using minimal detergent solubilization of cells followed by density gradient isolation, we found that GPI-linked CD52 is concentrated within glycolipid-enriched membrane domains of CLL cells. Crosslinking of CD52 with alemtuzumab and a secondary antibody led to patching and capping of antibody-antigen complexes on most of the CLL samples examined. Furthermore, fluorescence microscopy analysis showed colocalization of cholera toxin subunit B and crosslinked alemtuzumab. This is evidence that alemtuzumab treatment leads to aggregation of glycolipid-enriched domains upon the CLL plasma membrane surface. Membrane cholesterol depletion inhibited alemtuzumab-induced glycolipid-enriched aggregation, and further supports our hypothesis that crosslinking alemtuzumab upon the membrane surface pulls glycolipid-enriched domains together into relatively large, stable aggregates. Inhibition of alemtuzumab-induced CLL cell death by MbCD treatment of cellular membranes with concurrent loss of glycolipid-enriched membrane caps, suggests that it is the aggregation of glycolipid-enriched membrane domains that triggers the death pathway. Inhibition of F-actin polymerization reduced both alemtuzumab-induced capping and CLL cell death. The data presented here are in agreement with a large body of work that supports a link between GPI-linked proteins, glycolipid-enriched membrane domains, the underlying actin cytoskeleton and in some cases, initiation of cell death. Models that invoke aggregation of glycolipid-enriched membrane domains, with subsequent formation of signaling complexes and activation of cell death pathways have been proposed. 54, 55 Our data, obtained using primary CLL cells and alemtuzumab, an antibody with clinical activity against resistant disease, provides further support for these models. In addition to CD52, the integral membrane proteins CD20 and HLA-DR are favored targets for antibody-based treatment of CLL. Crosslinking of CD20 with rituximab or HLA-DR with apolizumab on the surface of primary CLL cells is cytotoxic in the absence of complement or accessory effector cells. 22, 26 As with CD52, some 56, 57 but not all groups 58 have demonstrated that ligated CD20 is associated with glycolipid-enriched membrane domains. In studies where CD20 lipid raft recruitment has been noted, it has been suggested that the direct apoptotic effect of rituximab on CLL cells observed in vitro may be due to the clustering of the glycolipid-enriched domains with subsequent activation of src-family tyrosine kinases. 54 Another group has shown that CD20 antibodies with a specificity that allows redistribution of CD20 into lipid rafts are effective inducers of CDC, whereas antibodies that cannot redistribute CD20 induce apoptosis. 58 As alemtuzumab ligation of CD52 recruits this antigen further to lipid rafts, it is possible that alemtuzumab is a weak apoptosis inducer and alternative antibodies with different specificities could be more potent.
We noted that CLL cells are more sensitive to the direct cytotoxic effect of alemtuzumab than normal T cells. The difference is probably not attributable to a lower CD52 density on the surface of the T cells than the CLL cells. We have shown comparable alemtuzumab and secondary antibody binding on CLL and normal T cells. Rather, we propose that CD52-associated signaling molecules within DIGs differ in CLL and T cells. The correlation between alemtuzumab-induced capping and cell death we observed, suggests that differences in membrane-associated proteins involved in the aggregation of alemtuzumab/CD52 complexes upon the membrane surface are responsible for the varied cytotoxic response of CLL and T cells to alemtuzumab. The observed difference in the direct cytotoxic effect of alemetuzumab toward CLL cells may have a practical application. Engineering anti-CD52 antibodies to favor the direct cytotoxic mechanism may allow a more selective cytoreduction in the treatment of CLL and other lymphoproliferative diseases.
